213 related articles for article (PubMed ID: 21284488)
1. Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant.
Li N; Yu YZ; Yu WY; Sun ZW
Immunopharmacol Immunotoxicol; 2011 Mar; 33(1):211-9. PubMed ID: 21284488
[TBL] [Abstract][Full Text] [Related]
2. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A.
Yu YZ; Zhang SM; Sun ZW; Wang S; Yu WY
Vaccine; 2007 Dec; 25(52):8843-50. PubMed ID: 18022294
[TBL] [Abstract][Full Text] [Related]
3. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors.
Yu Y; Yu J; Li N; Wang S; Yu W; Sun Z
Vaccine; 2009 Oct; 27(44):6148-53. PubMed ID: 19712769
[TBL] [Abstract][Full Text] [Related]
4. Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant.
Ma Y; An HJ; Wei XQ; Xu Q; Yu YZ; Sun ZW
Hum Vaccin Immunother; 2013 Feb; 9(2):242-9. PubMed ID: 23291932
[TBL] [Abstract][Full Text] [Related]
5. Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.
Yu YZ; Liu S; Ma Y; Gong ZW; Wang S; Sun ZW
Hum Vaccin Immunother; 2014; 10(7):1874-9. PubMed ID: 25424795
[TBL] [Abstract][Full Text] [Related]
6. Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine.
Yu YZ; Sun ZW; Li N; Wang S; Wang RL; Yu WY
Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):261-6. PubMed ID: 18932057
[TBL] [Abstract][Full Text] [Related]
7. Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors.
Yu YZ; Guo JP; An HJ; Zhang SM; Wang S; Yu WY; Sun ZW
Vaccine; 2013 May; 31(20):2427-32. PubMed ID: 23583890
[TBL] [Abstract][Full Text] [Related]
8. Distinct immune responses of recombinant plasmid DNA replicon vaccines expressing two types of antigens with or without signal sequences.
Yu YZ; Li N; Wang WB; Wang S; Ma Y; Yu WY; Sun ZW
Vaccine; 2010 Nov; 28(47):7529-35. PubMed ID: 20854897
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection.
Zheng Q; Fan D; Gao N; Chen H; Wang J; Ming Y; Li J; An J
Vaccine; 2011 Jan; 29(4):763-71. PubMed ID: 21095256
[TBL] [Abstract][Full Text] [Related]
10. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
[TBL] [Abstract][Full Text] [Related]
11. Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice.
Qing Y; Chen M; Zhao J; Hu H; Xu H; Ling N; Peng M; Ren H
Vaccine; 2010 Jun; 28(26):4301-7. PubMed ID: 20430121
[TBL] [Abstract][Full Text] [Related]
12. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects.
Bowne WB; Wolchok JD; Hawkins WG; Srinivasan R; Gregor P; Blachere NE; Moroi Y; Engelhorn ME; Houghton AN; Lewis JJ
Cytokines Cell Mol Ther; 1999 Dec; 5(4):217-25. PubMed ID: 10850386
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene.
Zhang X; Divangahi M; Ngai P; Santosuosso M; Millar J; Zganiacz A; Wang J; Bramson J; Xing Z
Vaccine; 2007 Jan; 25(7):1342-52. PubMed ID: 17052817
[TBL] [Abstract][Full Text] [Related]
14. Enhanced effects of DNA vaccine against botulinum neurotoxin serotype A by targeting antigen to dendritic cells.
Chen BY; Zhou G; Li QL; Lu JS; Shi DY; Pang XB; Zhou XW; Yu YZ; Huang PT
Immunol Lett; 2017 Oct; 190():118-124. PubMed ID: 28802641
[TBL] [Abstract][Full Text] [Related]
15. Improved immunogenicity and protective efficacy of a replicon DNA vaccine encoding the Hc domain of botulinum neurotoxin serotype A by electric pulses and protein boosting.
Yu YZ; Li N; Wang S; Yu WY; Sun ZW
Immunopharmacol Immunotoxicol; 2009; 31(3):397-404. PubMed ID: 19555205
[TBL] [Abstract][Full Text] [Related]
16. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses.
Yoon HA; Aleyas AG; George JA; Park SO; Han YW; Lee JH; Cho JG; Eo SK
Microbiol Immunol; 2006; 50(2):83-92. PubMed ID: 16490926
[TBL] [Abstract][Full Text] [Related]
17. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system.
Lee JS; Pushko P; Parker MD; Dertzbaugh MT; Smith LA; Smith JF
Infect Immun; 2001 Sep; 69(9):5709-15. PubMed ID: 11500447
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of Japanese encephalitis virus prM-E-NS1 antigen with granulocyte-macrophage colony-stimulating factor enhances humoral and anti-virus immunity after DNA vaccination.
Gao N; Chen W; Zheng Q; Fan DY; Zhang JL; Chen H; Gao GF; Zhou DS; An J
Immunol Lett; 2010 Mar; 129(1):23-31. PubMed ID: 20064558
[TBL] [Abstract][Full Text] [Related]
19. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine.
Weiss WR; Ishii KJ; Hedstrom RC; Sedegah M; Ichino M; Barnhart K; Klinman DM; Hoffman SL
J Immunol; 1998 Sep; 161(5):2325-32. PubMed ID: 9725227
[TBL] [Abstract][Full Text] [Related]
20. Enhanced potency of individual and bivalent DNA replicon vaccines or conventional DNA vaccines by formulation with aluminum phosphate.
Yu YZ; Wang WB; Li N; Wang S; Yu WY; Sun ZW
Biologicals; 2010 Nov; 38(6):658-63. PubMed ID: 20805035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
